contact us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right.

           

123 Street Avenue, City Town, 99999

(123) 555-6789

email@address.com

 

You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.

Eli Lilly raised prices on 9 drugs last week

Arden's Day Blog

Arden's Day is a type I diabetes care giver blog written by author Scott Benner. Scott has been a stay-at-home dad since 2000, he is the author of the award winning parenting memoir, 'Life Is Short, Laundry Is Eternal'. Arden's Day is an honest and transparent look at life with diabetes - since 2007.

type I diabetes, parent of type I child, diabetes Blog, OmniPod, DexCom, insulin pump, CGM, continuous glucose monitor, Arden, Arden's Day, Scott Benner, JDRF, diabetes, juvenile diabetes, daddy blog, blog, stay at home parent, DOC, twitter, Facebook, @ardensday, 504 plan, Life Is Short, Laundry Is Eternal, Dexcom SHARE, 生命是短暂的,洗衣是永恒的, Shēngmìng shì duǎnzàn de, xǐyī shì yǒnghéng de

Eli Lilly raised prices on 9 drugs last week

Scott Benner

from CNBC

Humalog and Humulin (7.8 percent)

Indianapolis drug giant Eli Lilly raised list prices of nine of its medicines last week between 6 and 10 percent, according to data obtained by CNBC.

The increases, taken on May 2, were for drugs including the blood thinner Effient (9.9 percent), the psoriasis drug Taltz (6.9 percent) and the insulins Humalog and Humulin (7.8 percent).

The increases fit a pattern at Lilly and many other drugmakers of single-digit percentage hikes once or twice a year, despite political pressure and intense scrutiny of the practices. Lilly has come under fire for the price of its insulin drugs in particular, leading Senator Bernie Sanders to call for a federal investigation into collusion. Lilly and other insulin makers have denied any such activity.

Lilly confirmed the price increases in an emailed statement to CNBC, and noted the list prices "do not reflect the significant discounts and rebates that we provide to ensure patients have adequate access to our medicines."

"The net price increase that Lilly recognizes is significantly less," spokesman Mark Taylor wrote. "In fact, in 2016, the average discount to list price on our U.S. portfolio rose to 50 percent and net prices rose just 2.4 percent in the U.S."

You can read the entire article on CNBC